Consolidated Planning Corp Has $289,000 Stake in Aflac Incorporated (NYSE:AFL)

Consolidated Planning Corp increased its position in shares of Aflac Incorporated (NYSE:AFL) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,500 shares of the financial services provider’s stock after buying an additional 153 shares during the period. Consolidated Planning Corp’s holdings in Aflac were worth $289,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Flputnam Investment Management Co. increased its holdings in shares of Aflac by 0.5% in the fourth quarter. Flputnam Investment Management Co. now owns 25,031 shares of the financial services provider’s stock valued at $2,065,000 after purchasing an additional 122 shares during the last quarter. Baystate Wealth Management LLC increased its holdings in shares of Aflac by 24.1% in the third quarter. Baystate Wealth Management LLC now owns 675 shares of the financial services provider’s stock valued at $52,000 after purchasing an additional 131 shares during the last quarter. Brighton Jones LLC increased its holdings in shares of Aflac by 2.3% in the third quarter. Brighton Jones LLC now owns 6,156 shares of the financial services provider’s stock valued at $472,000 after purchasing an additional 136 shares during the last quarter. MV Capital Management Inc. increased its holdings in shares of Aflac by 3.7% in the third quarter. MV Capital Management Inc. now owns 3,779 shares of the financial services provider’s stock valued at $290,000 after purchasing an additional 136 shares during the last quarter. Finally, Simon Quick Advisors LLC grew its stake in shares of Aflac by 4.9% in the fourth quarter. Simon Quick Advisors LLC now owns 2,950 shares of the financial services provider’s stock valued at $243,000 after acquiring an additional 139 shares in the last quarter. 67.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AFL has been the topic of several research reports. Raymond James upped their price target on shares of Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Morgan Stanley upped their price target on shares of Aflac from $80.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Evercore ISI downgraded shares of Aflac from an “in-line” rating to an “underperform” rating and upped their price target for the company from $76.00 to $78.00 in a research note on Thursday, January 4th. Keefe, Bruyette & Woods upped their price target on shares of Aflac from $83.00 to $87.00 and gave the company a “market perform” rating in a research note on Wednesday, April 10th. Finally, StockNews.com downgraded shares of Aflac from a “hold” rating to a “sell” rating in a research note on Wednesday, April 10th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $82.15.

Aflac Price Performance

Shares of AFL stock traded down $0.12 on Friday, reaching $83.61. The company had a trading volume of 1,839,028 shares, compared to its average volume of 2,169,786. The stock has a market capitalization of $48.11 billion, a PE ratio of 10.79, a price-to-earnings-growth ratio of 2.29 and a beta of 0.91. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. Aflac Incorporated has a one year low of $64.10 and a one year high of $86.26. The business’s 50-day moving average is $82.69 and its 200 day moving average is $81.77.

Aflac (NYSE:AFL) last posted its earnings results on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The company had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $4.44 billion. Aflac had a return on equity of 17.59% and a net margin of 24.92%. During the same period last year, the company posted $1.29 EPS. Equities research analysts forecast that Aflac Incorporated will post 6.41 EPS for the current fiscal year.

Insider Transactions at Aflac

In other news, Director Thomas J. Kenny sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total value of $423,100.00. Following the completion of the transaction, the director now owns 17,920 shares of the company’s stock, valued at $1,516,390.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Aflac news, SVP Albert Riggieri sold 8,000 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $83.34, for a total transaction of $666,720.00. Following the completion of the sale, the senior vice president now owns 32,825 shares of the company’s stock, valued at approximately $2,735,635.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thomas J. Kenny sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $84.62, for a total transaction of $423,100.00. Following the sale, the director now directly owns 17,920 shares of the company’s stock, valued at approximately $1,516,390.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,493 shares of company stock valued at $3,765,706. 0.90% of the stock is currently owned by insiders.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.